Startups

Johnson & Johnson joins WellDoc’s big funding round

Along with an investment, a Johnson & Johnson subsidiary focused on diabetes care will integrate WellDoc's app.

WellDoc’s Series B just got closer to $30 million.
The Midtown-based company, which makes an app for managing type 2 diabetes, announced a total of $29.5 million in its Series B on Tuesday. In December, company officials said they raised $22 million, led by Samsung Ventures and Merck Global Health Innovation Fund.
Though the company is not disclosing how much money each investor provided, a new addition is Johnson & Johnson Innovation — the venture arm of the consumer products giant.
Along with the investment, WellDoc’s BlueStar app will be used in products made by LifeScan, a Johnson & Johnson company in the diabetes space. BlueStar will be integrated into LifeScan’s OneTouch digital glucose monitoring system. BlueStar, which is FDA-approved and must be prescribed, is designed to help patients self-manage when they are outside the healthcare system through motivation, education and behavioral coaching in real time.
“This is a very significant step forward for our company and has the potential to make a difference in the lives of millions of people living with this chronic disease,” WellDoc CEO Kevin McRaith said in a statement.
BlueStar is also integrated into Samsung’s S Health.

Companies: WellDoc
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Donate to the Journalism Fund

Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.

Trending

Startups with public sector DNA compete at George Mason investor breakfast

West Virginia ranks last in innovation. Meet the people trying to change that.

How do H-1B visas work? Here’s everything you need to know

Tech hiring collapsed. What signals are on the horizon?

Technically Media